The digital health firm Klineo, situated in Paris, France, has secured €2 million in investment.
Business angels participated in a round led by BPI France.
The firm plans to utilize the money to broaden its business reach throughout Europe and the US, as well as to continue expanding operations and its research and development activities to address other forms of cancer.
Under the direction of CTO Nicolas Drizard and CEO Thomas Peyresblanques, Klineo offers a platform driven by AI that links medical professionals and patients participating in cancer clinical trials.
“Our goal is to ensure equitable access to clinical trials, and the confidence and support of our investors reflects the significance of this goal. This round of funding will allow us to expand our platform to all types of cancer, thereby accelerating the inclusion of patients in clinical trials.”
CEO Thomas Peyresblanques
In 2022, the firm, in partnership with the Collectif Triplettes Roses, established a national platform on triple negative breast cancer and established a trial project at the Gustave Roussy Institute. Klineo expanded its platform to include more malignancies (skin, lymphoma, breast, etc.) in 2023, with the goal of covering all cancers by the end of 2024.
Its Investors:
- Altos Ventures
- Ascend Vietnam Ventures
- Decisive Capital Management
- FJ Labs
- KDV Capital
A number of stakeholders, including the BPI, the Pfizer Healthcare Hub, Wilco, Onconumérique, PariSanté Campus, and Unicancer, support Klineo as well.
Regarding Klineo:
It is founded in 2021 in Paris,France. Klineo is Digital clinical data and trial management tool for doctors and researchers. The company has developed software that assists professionals to manage clinical trial documents and patient information. It can be used for trial recruitment and other clinical processes.
